CY1105501T1 - Συνδυασμοι φαρμακων (π.χ. chlorpromazine και pentamidine) για την αντιμετωπιση νεοπλαστικων διαταραχων - Google Patents
Συνδυασμοι φαρμακων (π.χ. chlorpromazine και pentamidine) για την αντιμετωπιση νεοπλαστικων διαταραχωνInfo
- Publication number
- CY1105501T1 CY1105501T1 CY20061100653T CY061100653T CY1105501T1 CY 1105501 T1 CY1105501 T1 CY 1105501T1 CY 20061100653 T CY20061100653 T CY 20061100653T CY 061100653 T CY061100653 T CY 061100653T CY 1105501 T1 CY1105501 T1 CY 1105501T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pentamidine
- chlorpromazine
- treatment
- drug combinations
- neoplastic disorders
- Prior art date
Links
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001076 chlorpromazine Drugs 0.000 title abstract 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004448 pentamidine Drugs 0.000 title abstract 2
- 239000000890 drug combination Substances 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Η εφεύρεση αναφέρεται σε μία μέθοδο για τη θεραπευτική αγωγή σ' έναν ασθενή που πάσχει από καρκίνο ή άλλο νεόπλασμα, με χορήγηση στον ασθενή (i) chlorpromazine ή έναν μεταβολίτη ή ανάλογο αυτού· και (ii) pentamidine ή έναν μεταβολίτη ή ανάλογο αυτού ταυτόχρονα ή μέσα σε 14 ημέρες το ένα από το άλλο σε ποσότητες που επαρκούν για την αναστολή της ανάπτυξης του νεοπλάσματος.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/706,929 US6569853B1 (en) | 2000-11-06 | 2000-11-06 | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
PCT/US2001/047959 WO2002058684A2 (en) | 2000-11-06 | 2001-10-30 | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105501T1 true CY1105501T1 (el) | 2010-04-28 |
Family
ID=24839666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061100653T CY1105501T1 (el) | 2000-11-06 | 2006-05-19 | Συνδυασμοι φαρμακων (π.χ. chlorpromazine και pentamidine) για την αντιμετωπιση νεοπλαστικων διαταραχων |
Country Status (29)
Country | Link |
---|---|
US (4) | US6569853B1 (el) |
EP (1) | EP1339399B1 (el) |
JP (1) | JP2004517915A (el) |
KR (1) | KR100720205B1 (el) |
CN (1) | CN1484525A (el) |
AR (1) | AR035500A1 (el) |
AT (1) | ATE318590T1 (el) |
AU (1) | AU2002246636B8 (el) |
BG (1) | BG107831A (el) |
BR (1) | BR0115166A (el) |
CA (1) | CA2436799C (el) |
CY (1) | CY1105501T1 (el) |
DE (1) | DE60117615T2 (el) |
DK (1) | DK1339399T3 (el) |
EE (1) | EE200300212A (el) |
ES (1) | ES2258566T3 (el) |
HR (1) | HRP20030460A2 (el) |
HU (1) | HUP0400529A3 (el) |
IL (1) | IL155795A0 (el) |
IS (1) | IS2457B (el) |
MX (1) | MXPA03003960A (el) |
NO (1) | NO20032036L (el) |
NZ (1) | NZ525773A (el) |
PL (1) | PL362690A1 (el) |
PT (1) | PT1339399E (el) |
RU (1) | RU2286769C2 (el) |
SK (1) | SK5452003A3 (el) |
TW (1) | TWI259077B (el) |
WO (1) | WO2002058684A2 (el) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1231910T3 (da) * | 1999-11-16 | 2009-08-31 | Oncozyme Pharma Inc | Pentamidin til behandling af cancer |
DE10015818A1 (de) * | 2000-03-30 | 2001-10-18 | Infineon Technologies Ag | Biosensor und Verfahren zum Ermitteln makromolekularer Biopolymere mit einem Biosensor |
US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
US20030049320A1 (en) * | 2000-12-18 | 2003-03-13 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
US6992082B2 (en) * | 2001-01-19 | 2006-01-31 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
WO2002069949A2 (en) * | 2001-03-06 | 2002-09-12 | Prendergast Patrick T | Combination therapy for reduction of toxycity of chemotherapeutic agents |
EP1401426B1 (en) * | 2001-05-31 | 2008-07-23 | The Cleveland Clinic Foundation | Ptpase inhibitors and method of using same |
FR2825279B1 (fr) * | 2001-06-01 | 2005-04-08 | Molecular Engines Lab | Medicament utile dans le traitement du cancer |
US20050215629A1 (en) * | 2001-09-07 | 2005-09-29 | Taolin Yi | PTPase inhibitors and methods of using the same |
US20040010045A1 (en) * | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
CA2459793A1 (en) * | 2001-09-07 | 2003-08-28 | The Cleveland Clinic Foundation | Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
US7544681B2 (en) * | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
AU2004201240B2 (en) * | 2001-09-27 | 2008-08-07 | Bar Ilan University | Conjugated Psychotropic Drugs and Uses Thereof |
US8053477B2 (en) * | 2002-03-29 | 2011-11-08 | University Of Maryland, Baltimore | Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same |
WO2003092616A2 (en) * | 2002-05-01 | 2003-11-13 | The Cleveland Clinic Foundation | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
BR0312597A (pt) * | 2002-07-11 | 2005-05-10 | Combinatorx Inc | Combinações de drogas para o tratamento de neoplasmas |
ES2343411T3 (es) * | 2003-03-26 | 2010-07-30 | Synergy Biosystems Ltd. | Procedimientos para identificar agentes biologicamente activos y combinaciones sinergicas. |
CA2534816A1 (en) * | 2003-06-12 | 2004-12-23 | Evan Newell | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors |
US20050054708A1 (en) * | 2003-07-28 | 2005-03-10 | Nichols Matthew James | Combinations of drugs for the treatment of neoplasms |
US20050080075A1 (en) * | 2003-08-25 | 2005-04-14 | Nichols M. James | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms |
KR20070012618A (ko) * | 2003-09-18 | 2007-01-26 | 콤비네이토릭스, 인코포레이티드 | 신생물 치료용 약의 조합 |
US20050158320A1 (en) * | 2003-11-12 | 2005-07-21 | Nichols M. J. | Combinations for the treatment of proliferative diseases |
TW200526777A (en) * | 2003-11-12 | 2005-08-16 | Combinatorx Inc | Combinations for the treatment of proliferative diseases |
US20050100508A1 (en) * | 2003-11-12 | 2005-05-12 | Nichols M. J. | Methods for identifying drug combinations for the treatment of proliferative diseases |
ATE532517T1 (de) | 2003-11-13 | 2011-11-15 | Noa Sic Aps | Thioridazin und seine derivate zur umkehr von antimikrobieller arzneimittelresistenz |
WO2005070126A2 (en) | 2004-01-08 | 2005-08-04 | The Regents Of The University Of Colorado | Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors |
US20100173864A1 (en) * | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
WO2005094322A2 (en) | 2004-03-29 | 2005-10-13 | University Of South Florida | Effective treatment of tumors and cancer with triciribine and related compounds |
US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
US20110008327A1 (en) * | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
EP1744781B1 (en) | 2004-04-30 | 2012-07-04 | BKG Pharma ApS | Treatment of infectious diseases |
WO2005117847A2 (en) * | 2004-06-02 | 2005-12-15 | Combinatorx, Incorporated | Methods and compounds for the treatment of neoplasms |
CA2595156A1 (en) * | 2005-01-19 | 2006-07-27 | The Trustees Of The University Of Pennsylvania | Regulation of autophagy and cell survival |
TW200719903A (en) * | 2005-04-19 | 2007-06-01 | Combinatorx Inc | Compositions for the treatment of neoplasms |
EP1877060A2 (en) * | 2005-04-28 | 2008-01-16 | The Regents of the University of Colorado | Therapeutic bifunctional compounds |
CA2611738A1 (en) * | 2005-05-02 | 2006-11-09 | The Regents Of The University Of Colorado | Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism andglycolysis inhibition |
JP5700909B2 (ja) | 2005-05-04 | 2015-04-15 | メディゲーネ アクチエンゲゼルシャフトMediGene AG | パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法 |
DE102005024017A1 (de) * | 2005-05-25 | 2006-11-30 | Merck Patent Gmbh | Chinazolinone |
ES2400772T3 (es) * | 2005-06-07 | 2013-04-12 | Ramot At Tel Aviv University Ltd. | Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas |
CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
WO2007082052A2 (en) * | 2006-01-11 | 2007-07-19 | The Cleveland Clinic Foundation | Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
BRPI0709075A2 (pt) | 2006-03-20 | 2011-10-11 | Medigene Ag | tratamento de cáncer de mama triplo receptor negativo |
US20080226596A1 (en) * | 2006-06-19 | 2008-09-18 | Taolin Yi | Therapeutic compositions and methods useful in treating hepatitis |
WO2007149381A2 (en) * | 2006-06-19 | 2007-12-27 | The Cleveland Clinic Foundation | Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer |
JP5192485B2 (ja) * | 2006-07-17 | 2013-05-08 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 向精神性薬物またはgabaアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のcns障害を治療するためのそれらの使用 |
MX2009007235A (es) * | 2007-01-05 | 2009-10-16 | Bkg Pharma Aps | "derivados de tioxanteno utiles para el tratamiento de enfermedades infecciosas.". |
DK2124857T3 (en) * | 2007-01-09 | 2017-07-03 | Fovea Pharmaceuticals | DEVICE FOR INTRAOCULAR INJECTION |
DE102007013854A1 (de) | 2007-03-20 | 2008-09-25 | Merck Patent Gmbh | Tetrahydrochinoline |
DE102007013856A1 (de) | 2007-03-20 | 2008-09-25 | Merck Patent Gmbh | Substituierte Tetrahydropyrrolochinoline |
DE102007013855A1 (de) | 2007-03-20 | 2008-09-25 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
US20110009351A1 (en) * | 2007-05-09 | 2011-01-13 | Traffick Therepeutics Inc. | Screening assay to identify correctors of protein trafficking defects |
CN101138558B (zh) * | 2007-09-13 | 2010-08-25 | 汕头大学医学院 | 喷他脒及死亡结构域受体配体联合应用 |
EP2194981B1 (en) * | 2007-10-05 | 2011-11-23 | Université de Mons-Hainaut | Bisbenzimidazoles as antimalarial agents |
WO2009101616A1 (en) * | 2008-02-11 | 2009-08-20 | Ramot At Tel Aviv University Ltd. | Novel conjugates for treating neurodegenerative diseases and disorders |
WO2009148623A2 (en) * | 2008-06-05 | 2009-12-10 | Stc.Unm | Methods and related compositions for the treatment of cancer |
WO2010009332A1 (en) * | 2008-07-18 | 2010-01-21 | Immune Control, Inc. | Binding and inhibiting 5-ht4 receptor |
US9034389B2 (en) | 2009-03-11 | 2015-05-19 | Stable Solutions Llc | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions |
US8993625B2 (en) | 2009-03-11 | 2015-03-31 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle |
JP2012525371A (ja) * | 2009-05-01 | 2012-10-22 | オンコザイム・ファーマ・インコーポレイテッド | 癌を治療するためのペンタミジンの組み合わせ |
EP2433133A2 (en) | 2009-05-20 | 2012-03-28 | Universite De Geneve | Mitochondrial activity inhibitors of cancer-initiating cells and use thereof |
US20120277193A1 (en) * | 2009-09-21 | 2012-11-01 | President And Fellows Of Harvard College | Synergistic Combination Therapy |
WO2011070579A1 (en) * | 2009-12-09 | 2011-06-16 | Biolinerx Ltd. | Methods of improving cognitive functions |
US20130165417A1 (en) * | 2010-04-23 | 2013-06-27 | University Of Florida Research Foundation | Methods and compositions for treating ace2-related disorders |
US8916610B2 (en) | 2010-09-22 | 2014-12-23 | Ramot At Tel-Aviv University Ltd. | Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same |
SI2550963T1 (sl) * | 2011-07-25 | 2017-05-31 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Estri amidoksim karboksilne kisline pentamidina kot predzdravila in njihova uporaba kot zdravila |
WO2013017637A1 (en) * | 2011-08-02 | 2013-02-07 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Selective inhibition of malt1 protease by phenothiazine derivatives |
WO2014086478A1 (en) * | 2012-12-03 | 2014-06-12 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of malt1 protease |
BR112015014836A2 (pt) | 2012-12-21 | 2017-07-11 | Verlyx Pharma Inc | método para tratamento alvo de uma ou mais condições do fígado, e, uso oral de uma quantidade terapeuticamente eficaz de pelo menos um análogo de diamidina ou um sal farmaceuticamente aceitável da mesma |
RU2530651C1 (ru) * | 2013-11-06 | 2014-10-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство, обладающее противовоспалительным и антифибротическим действием в легочной ткани при цитостатическом воздействии |
KR101538264B1 (ko) * | 2014-01-24 | 2015-07-20 | 계명대학교 산학협력단 | 티오리다진과 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물 |
CN105255887B (zh) * | 2015-07-17 | 2018-05-18 | 四川大学 | 一种重组慢病毒及其在制备治疗可卡因成瘾的药物中的用途 |
WO2020082037A1 (en) * | 2018-10-19 | 2020-04-23 | Auransa Inc. | Methods for treating a subtype of small cell lung cancer |
CN109793727A (zh) * | 2019-03-13 | 2019-05-24 | 湖北科技学院 | 一种有效抗恶性肿瘤的药物组合物及其应用 |
KR102562739B1 (ko) * | 2020-09-11 | 2023-08-03 | 연세대학교 산학협력단 | 암의 기원 세포의 사멸용 약학적 조성물 |
KR102315103B1 (ko) * | 2021-01-21 | 2021-10-20 | 주식회사 뉴캔서큐어바이오 | 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2645640A (en) * | 1953-07-14 | Phenthiazine derivatives | ||
GB1288376A (el) | 1968-10-29 | 1972-09-06 | ||
DE3827974A1 (de) * | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen |
US5104858A (en) | 1988-09-29 | 1992-04-14 | Yale University | Sensitizing multidrug resistant cells to antitumor agents |
CH681780A5 (en) * | 1991-02-25 | 1993-05-28 | Patrinove | Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s) |
US5428051A (en) * | 1992-10-13 | 1995-06-27 | University Of North Carolina | Methods of combating pneumocystis carinii pneumonia and compounds useful therefor |
US5443962A (en) * | 1993-06-04 | 1995-08-22 | Mitotix, Inc. | Methods of identifying inhibitors of cdc25 phosphatase |
US5521189A (en) * | 1994-05-06 | 1996-05-28 | The University Of Nc At Ch | Methods of treating pneumocystis carinii pneumonia |
US5602172A (en) * | 1994-05-06 | 1997-02-11 | The University Of North Carolina At Chapel Hill | Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor |
US5770585A (en) | 1995-05-08 | 1998-06-23 | Kaufman; Robert J. | Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal |
US5643935A (en) * | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
US5723495A (en) * | 1995-11-16 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Benzamidoxime prodrugs as antipneumocystic agents |
WO1998000018A1 (en) * | 1996-07-03 | 1998-01-08 | Prm Pharmaceuticals, Inc. | Berberine alkaloids as a treatment for chronic, protozoally-induced diarrhea |
US6008247A (en) * | 1998-02-27 | 1999-12-28 | The University Of North Carolina At Chapel Hill | 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents |
HUP0102612A2 (hu) | 1998-03-12 | 2001-11-28 | Novo Nordisk A/S | Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények |
ATE239003T1 (de) * | 1998-08-20 | 2003-05-15 | Univ North Carolina | Dibenzothiophene derivate und ihre verwendung |
CA2344445A1 (en) * | 1998-09-17 | 2000-03-23 | The University Of North Carolina At Chapel Hill | Antifungal activity of dicationic molecules |
JP3679943B2 (ja) * | 1999-03-02 | 2005-08-03 | 大日本印刷株式会社 | パターン形成体の製造方法 |
DK1231910T3 (da) | 1999-11-16 | 2009-08-31 | Oncozyme Pharma Inc | Pentamidin til behandling af cancer |
US6777433B2 (en) * | 1999-12-22 | 2004-08-17 | Merck Frosst Canada & Co. | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates |
AU2001258784A1 (en) * | 2000-05-22 | 2001-12-03 | Takeda Chemical Industries Ltd. | Tyrosine phosphatase inhibitors |
US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
US6642221B1 (en) * | 2000-11-15 | 2003-11-04 | Parker Hughes Institute | Vanadium compounds as anti-proliferative agents |
US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
US20030161893A1 (en) * | 2001-09-07 | 2003-08-28 | Taolin Yi | PTPase inhibitors and methods of using the same |
BR0312597A (pt) * | 2002-07-11 | 2005-05-10 | Combinatorx Inc | Combinações de drogas para o tratamento de neoplasmas |
US20050054708A1 (en) * | 2003-07-28 | 2005-03-10 | Nichols Matthew James | Combinations of drugs for the treatment of neoplasms |
US20050080075A1 (en) * | 2003-08-25 | 2005-04-14 | Nichols M. James | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms |
KR20070012618A (ko) * | 2003-09-18 | 2007-01-26 | 콤비네이토릭스, 인코포레이티드 | 신생물 치료용 약의 조합 |
US20050158320A1 (en) * | 2003-11-12 | 2005-07-21 | Nichols M. J. | Combinations for the treatment of proliferative diseases |
US20050100508A1 (en) * | 2003-11-12 | 2005-05-12 | Nichols M. J. | Methods for identifying drug combinations for the treatment of proliferative diseases |
-
2000
- 2000-11-06 US US09/706,929 patent/US6569853B1/en not_active Expired - Fee Related
-
2001
- 2001-10-30 WO PCT/US2001/047959 patent/WO2002058684A2/en active IP Right Grant
- 2001-10-30 EP EP01994213A patent/EP1339399B1/en not_active Expired - Lifetime
- 2001-10-30 HU HU0400529A patent/HUP0400529A3/hu unknown
- 2001-10-30 AU AU2002246636A patent/AU2002246636B8/en not_active Ceased
- 2001-10-30 CN CNA018217230A patent/CN1484525A/zh active Pending
- 2001-10-30 ES ES01994213T patent/ES2258566T3/es not_active Expired - Lifetime
- 2001-10-30 DE DE60117615T patent/DE60117615T2/de not_active Expired - Fee Related
- 2001-10-30 DK DK01994213T patent/DK1339399T3/da active
- 2001-10-30 MX MXPA03003960A patent/MXPA03003960A/es active IP Right Grant
- 2001-10-30 NZ NZ525773A patent/NZ525773A/en unknown
- 2001-10-30 RU RU2003116898/14A patent/RU2286769C2/ru not_active IP Right Cessation
- 2001-10-30 KR KR1020037006212A patent/KR100720205B1/ko not_active IP Right Cessation
- 2001-10-30 AT AT01994213T patent/ATE318590T1/de not_active IP Right Cessation
- 2001-10-30 SK SK545-2003A patent/SK5452003A3/sk not_active Application Discontinuation
- 2001-10-30 EE EEP200300212A patent/EE200300212A/xx unknown
- 2001-10-30 IL IL15579501A patent/IL155795A0/xx unknown
- 2001-10-30 CA CA002436799A patent/CA2436799C/en not_active Expired - Fee Related
- 2001-10-30 PT PT01994213T patent/PT1339399E/pt unknown
- 2001-10-30 JP JP2002559018A patent/JP2004517915A/ja active Pending
- 2001-10-30 BR BR0115166-5A patent/BR0115166A/pt not_active Application Discontinuation
- 2001-10-30 PL PL01362690A patent/PL362690A1/xx not_active Application Discontinuation
- 2001-11-06 AR ARP010105193A patent/AR035500A1/es not_active Application Discontinuation
- 2001-11-06 TW TW090127505A patent/TWI259077B/zh not_active IP Right Cessation
-
2003
- 2003-01-21 US US10/347,714 patent/US6846816B2/en not_active Expired - Fee Related
- 2003-05-05 IS IS6806A patent/IS2457B/is unknown
- 2003-05-06 NO NO20032036A patent/NO20032036L/no not_active Application Discontinuation
- 2003-05-20 BG BG107831A patent/BG107831A/bg unknown
- 2003-06-06 HR HR20030460A patent/HRP20030460A2/hr not_active Application Discontinuation
-
2004
- 2004-12-28 US US11/024,303 patent/US7148216B2/en not_active Expired - Fee Related
-
2006
- 2006-05-19 CY CY20061100653T patent/CY1105501T1/el unknown
- 2006-12-07 US US11/635,704 patent/US20070099906A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105501T1 (el) | Συνδυασμοι φαρμακων (π.χ. chlorpromazine και pentamidine) για την αντιμετωπιση νεοπλαστικων διαταραχων | |
CY1118206T1 (el) | Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη | |
NO20061325L (no) | Kombinasjon av legemidler for behandling av neoplasmer | |
CY1117656T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
CY1111153T1 (el) | Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης | |
EA200100573A1 (ru) | Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии | |
CY1109340T1 (el) | Μεθοδοι θεραπειας bcl-2 διαταραχης χρησιμοποιωντας bcl-2 αντιπληροφοριακα ολιγομερη | |
CY1108436T1 (el) | Χορηγηση καψαϊκινοειδων | |
CY1108384T1 (el) | Διαδερμικη δοσολογια βουπρενορφινης για αναλγησια | |
DE50002293D1 (de) | Verwendung von csf-1-inhibitoren | |
ATE326956T1 (de) | Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität | |
ATE408601T1 (de) | Fredericamycin-derivate | |
EA200300544A1 (ru) | Эффективные противоопухолевые лекарственные средства | |
CY1106851T1 (el) | Χρηση του ζολεδρονικου οξεως για την θεραπεια του πονου | |
DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
CY1105584T1 (el) | Συνδυαστικη θεραπεια με ακτινοβολια και αναστολεα της cox - 2 για την αγωγη νεοπλασιων | |
ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
CY1109045T1 (el) | Ρετινοειδη για τη θεραπεια του εμφυσηματος | |
CY1109758T1 (el) | Ηλεκτρομαγνητικη διεγερση ασθενων με οστεοπορωση | |
BR0213100A (pt) | Combinações para o tratamento de distúrbios imuniinflamatórios | |
ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
CY1106026T1 (el) | Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας | |
CY1105545T1 (el) | Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας | |
WO2004006849A3 (en) | Combinations of drugs for the treatment of neoplasms |